An initiative to develop diagnostic technology that predicts the therapeutic efficacy of immune checkpoint inhibitors in advance, based on patent licensing and joint research with Kindai University and Kyoto University. It targets efficacy prediction for anti-PD-1 antibodies using immune checkpoint-related factors in blood.